Zelda Therapeutics Ltd (ASX:ZLD) executive chairman Harry Karelis updates Proactive Investors on the company’s global operations, following a January dual listing on the OTCQB Venture Market in the United States (OTCQB: ZLDAF).

“We have a two-pronged strategy. One is the clinical trials where we know there is some kind of effect, whether that's autism or pain or insomnia, so that's our clinical arm; and our pre-clinical arm is really spending money with some of the world's best researchers in studying cannabis as an anti-cancer agent… if we can replicate in the lab some of these anti-cancer effects then we believe that adds quite a lot of value for shareholders in Zelda in terms of then partnering with a traditional bio-pharmaceutical company... the data that we're generating and the intellectual property that we're developing is of value to those big bio-pharmaceutical companies that are geared up financially and otherwise for running these big complex trials," says Karelis.